Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Globe Newswire•02/10/2026•09:00 ET
0
Key Highlights
- ➤Atebimetinib enhances PD-1 checkpoint blockade in preclinical RAS mutant tumor models
- ➤Findings support planned Phase 2 atebimetinib and PD-1 blockade study in lung cancer
- ➤Immuneering (IMRX) will present findings at SITC annual meeting November 6, 2026
- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors -
- Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients -
Get started
Create a free account to read the full story.